Evidence Level
Pregnenolone is a neurosteroid that has demonstrated potential in specific psychiatric applications. Marx et al. (2009) conducted a randomized, placebo-controlled trial involving 21 schizophrenia patients and found that pregnenolone significantly improved negative symptoms, as measured by the SANS scores. Similarly, Brown et al. (2014) reported that in a double-blind, placebo-controlled trial with 73 participants, pregnenolone demonstrated significant antidepressant effects in individuals with bipolar disorder at higher doses.
The modulation of NMDA and GABA-A receptors by pregnenolone is well-documented in preclinical studies. However, large-scale randomized controlled trials (RCTs) evaluating its efficacy for common supplementation indications, such as anti-aging or cognitive enhancement in healthy adults, remain scarce. A meta-analysis by Li et al. (2026) of 74 RCTs involving 5,484 participants highlighted that while several anti-inflammatory drugs showed initial benefits for schizophrenia symptoms, these findings were tempered by high heterogeneity and significant publication bias, limiting their clinical significance.
Additionally, Stomati et al. (2000) conducted a randomized controlled trial with 36 postmenopausal women (ages 50-65) to assess the effects of DHEA supplementation over six months. The study found that daily administration of 50 mg DHEA increased levels of several hormones, including DHEA, DHEAS, androgens, estradiol, and beta-endorphin, while decreasing SHBG and gonadotropins. Although this study does not directly address pregnenolone's effects, it underscores the broader hormonal influences of neurosteroids.
Overall, while pregnenolone has shown potential in specific psychiatric contexts, further research is needed to establish its efficacy and safety for other indications.